IFN-γ released after the administration of anti-PD-1/anti-PD-L1 antibodies stimulates DC1s to produce interleukin (IL)-12b, which, in turn, promotes CD8+ T cell activation and tumor control [107]. The gene discussed is IFNG; the disease is neoplasm.